Blood cancers

News in brief: Immunoglobulin shortage; New CAR T approach for non-Hodgkin’s B-cell lymphoma; Arthritis drug identified as good candidate for high-risk paediatric leukaemias

Immunoglobulin medicine shortage The TGA has advised that Flebogamma 5% DIF immunoglobulin, normal (human) will be unavailable until 11 September 2021. The products distributed by Grifols Australia Pty Ltd are listed as a critical shortage on the TGA’s medicine shortage information site. Flebogamma is used for the treatment of primary immunodeficiency syndromes, myeloma or chronic ...

Already a member?

Login to keep reading.

© 2021 the limbic